# Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

> **NCT00489970** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1954 (actual)

## Conditions studied

- Acellular Pertussis
- Tetanus
- Diphtheria

## Interventions

- **PROCEDURE:** Taking of blood samples
- **BIOLOGICAL:** Boostrix
- **BIOLOGICAL:** Adacel

## Key facts

- **NCT ID:** NCT00489970
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-01
- **Primary completion:** 2011-09-01
- **Final completion:** 2016-03-01
- **Target enrollment:** 1954 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489970, "Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00489970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*